Securities Fraud Investigation Into GSK plc. (GSK) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R.Business Wire • 02/05/25
GSK Beats on Q4 Earnings & Sales, Stock Up on Raised Long-Term OutlookZacks Investment Research • 02/05/25
GSK Surges 7% After Bumping Its 2031 Outlook To North Of $50 BillionInvestors Business Daily • 02/05/25
GSK Q4 Earnings: Revenue And EPS Beat, Initiates $2.5 Billion Stock Buyback, Raises Long-Term Annual Sales Forecast To Over $50 BillionBenzinga • 02/05/25
GSK shares rise 5% as it navigates vaccines woes to upgrade sales targetProactive Investors • 02/05/25
GSK upgrades long-term sales target; but Arexvy's struggles are confirmedProactive Investors • 02/05/25
Shareholder Alert: Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against GSK plcBusiness Wire • 02/05/25
EMA Accepts GSK's Filing for Depemokimab in Two Respiratory DiseasesZacks Investment Research • 01/29/25
Influenza Vaccines Market Analysis 2025-2032: GlaxoSmithKline's Influenza Vaccines Sales Declined in 2024, Driven by Competitive Pressure and Volume Phasing in the US and Lower DemandGlobeNewsWire • 01/27/25
Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last?CNBC • 01/21/25
GSK's Jemperli Gets EU Nod for Expanded Use in Endometrial CancerZacks Investment Research • 01/21/25
Hallucinations in AI: How GSK is addressing a critical problem in drug developmentVentureBeat • 01/14/25